Isoalantolactone suppresses gallbladder cancer progression via inhibiting the ERK signalling pathway

References

• Al-Maghrabi J. 2020. Vimentin immunoexpression is associated with higher tumor grade, metastasis, and shorter survival in colorectal cancer. Int J Clin Exp Pathol. 13:493–500.
   PubMed Web of Science ®Google Scholar
• Asl ER, Amini M, Najafi S, Mansoori B, Mokhtarzadeh A, Mohammadi A, Lotfinejad P, Bagheri M, Shirjang S, Lotfi Z, et al. 2021. Interplay between MAPK/ERK signaling pathway and microRNAs: a crucial mechanism regulating cancer cell metabolism and tumor progression. Life Sci. 278:119499.
   PubMed Web of Science ®Google Scholar
• Azizi AA, Lamarca A, McNamara MG, Valle JW. 2021. Chemotherapy for advanced gallbladder cancer (GBC): a systematic review and meta-analysis. Crit Rev Oncol Hematol. 163:103328.
   PubMed Web of Science ®Google Scholar
• Baiu I, Visser B. 2018. Gallbladder cancer. JAMA. 320(12):1294.
   PubMedGoogle Scholar
• Bariselli S, Tzanoulinou S, Glangetas C, Prévost-Solié C, Pucci L, Viguié J, Bezzi P, O'Connor EC, Georges F, Lüscher C, et al. 2016. SHANK3 controls maturation of social reward circuits in the VTA. Nat Neurosci. 19(7):926–934.
   PubMed Web of Science ®Google Scholar
• Beliveau A, Mott JD, Lo A, Chen EI, Koller AA, Yaswen P, Muschler J, Bissell MJ. 2010. Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo. Genes Dev. 24(24):2800–2811.
   PubMed Web of Science ®Google Scholar
• Cai YL, Lin YX, Jiang LS, Ye H, Li FY, Cheng NS. 2020. A novel nomogram predicting distant metastasis in T1 and T2 gallbladder cancer: a SEER-based study. Int J Med Sci. 17(12):1704–1712.
   PubMed Web of Science ®Google Scholar
• Cao ZQ, Wang Z, Leng P. 2019. Aberrant N-cadherin expression in cancer. Biomed Pharmacother. 118:109320.
   PubMed Web of Science ®Google Scholar
• Chen P, Wang Y, Li J, Bo X, Wang J, Nan L, Wang C, Ba Q, Liu H, Wang H. 2021. Diversity and intratumoral heterogeneity in human gallbladder cancer progression revealed by single-cell RNA sequencing. Clin Transl Med. 11:e462.
   PubMed Web of Science ®Google Scholar
• Chen W, Li P, Liu Y, Yang Y, Ye X, Zhang F, Huang H. 2018. Isoalantolactone induces apoptosis through ROS-mediated ER stress and inhibition of STAT3 in prostate cancer cells. J Exp Clin Cancer Res. 37(1):309.
   PubMedGoogle Scholar
• Chen Y, Lian P, Liu Y, Xu K. 2015. Pachymic acid inhibits tumorigenesis in gallbladder carcinoma cells. Int J Clin Exp Med. 8:17781–17788.
   PubMed Web of Science ®Google Scholar
• Cingolani F, Liu Y, Shen Y, Wen J, Farris AB, Czaja MJ. 2022. Redundant functions of ERK1 and ERK2 maintain mouse liver homeostasis through down-regulation of bile acid synthesis. Hepatol Commun. 6(5):980–994.
   PubMed Web of Science ®Google Scholar
• Cubero FJ, Mohamed MR, Woitok MM, Zhao G, Hatting M, Nevzorova YA, Chen C, Haybaeck J, de Bruin A, Avila MA, et al. 2020. Loss of c-Jun N-terminal kinase 1 and 2 function in liver epithelial cells triggers biliary hyperproliferation resembling cholangiocarcinoma. Hepatol Commun. 4(6):834–851.
   PubMed Web of Science ®Google Scholar
• Ding YH, Song YD, Wu YX, He HQ, Yu TH, Hu YD, Zhang DP, Jiang HC, Yu KK, Li XZ, et al. 2019. Isoalantolactone suppresses LPS-induced inflammation by inhibiting TRAF6 ubiquitination and alleviates acute lung injury. Acta Pharmacol Sin. 40(1):64–74.
   PubMed Web of Science ®Google Scholar
• Dongre A, Weinberg RA. 2019. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 20(2):69–84.
   PubMed Web of Science ®Google Scholar
• Ehrenreiter K, Piazzolla D, Velamoor V, Sobczak I, Small JV, Takeda J, Leung T, Baccarini M. 2005. Raf-1 regulates Rho signaling and cell migration. J Cell Biol. 168(6):955–964.
   PubMed Web of Science ®Google Scholar
• Hundal R, Shaffer EA. 2014. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 6:99–109.
   PubMed Web of Science ®Google Scholar
• Khan M, Ding C, Rasul A, Yi F, Li T, Gao H, Gao R, Zhong L, Zhang K, Fang X, et al. 2012. Isoalantolactone induces reactive oxygen species mediated apoptosis in pancreatic carcinoma PANC-1 cells. Int J Biol Sci. 8(4):533–547.
   PubMed Web of Science ®Google Scholar
• Khokhlatchev AV, Canagarajah B, Wilsbacher J, Robinson M, Atkinson M, Goldsmith E, Cobb MH. 1998. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell. 93(4):605–615.
   PubMed Web of Science ®Google Scholar
• Kim EK, Choi EJ. 2015. Compromised MAPK signaling in human diseases: an update. Arch Toxicol. 89(6):867–882.
   PubMed Web of Science ®Google Scholar
• Kim MY, Lee H, Ji SY, Kim SY, Hwangbo H, Park SH, Kim GY, Park C, Leem SH, Hong SH, et al. 2021. Induction of apoptosis by isoalantolactone in human hepatocellular carcinoma Hep3B cells through activation of the ROS-dependent JNK signaling pathway. Pharmaceutics. 13(10):1627.
   PubMed Web of Science ®Google Scholar
• Lehmann K, Janda E, Pierreux CE, Rytömaa M, Schulze A, McMahon M, Hill CS, Beug H, Downward J. 2000. Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev. 14(20):2610–2622.
   PubMed Web of Science ®Google Scholar
• Li FS, Weng JK. 2017. Demystifying traditional herbal medicine with modern approach. Nat Plants. 3:17109.
   PubMed Web of Science ®Google Scholar
• Li Z, Qin B, Qi X, Mao J, Wu D. 2016. Isoalantolactone induces apoptosis in human breast cancer cells via ROS-mediated mitochondrial pathway and downregulation of SIRT1. Arch Pharm Res. 39(10):1441–1453.
   PubMed Web of Science ®Google Scholar
• Lu J, Kuang Z, Chen T, Ye C, Hou W, Tang L, Chen Y, He R. 2020. Isoalantolactone inhibits RANKL-induced osteoclast formation via multiple signaling pathways. Int Immunopharmacol. 84:106550.
   PubMed Web of Science ®Google Scholar
• Lu Z, Zhang G, Zhang Y, Hua P, Fang M, Wu M, Liu T. 2018. Isoalantolactone induces apoptosis through reactive oxygen species-dependent upregulation of death receptor 5 in human esophageal cancer cells. Toxicol Appl Pharmacol. 352:46–58.
   PubMed Web of Science ®Google Scholar
• Lv X, Chen J, He J, Hou L, Ren Y, Shen X, Wang Y, Ji T, Cai X. 2022. Gasdermin D-mediated pyroptosis suppresses liver regeneration after 70% partial hepatectomy. Hepatol Commun. 6(9):2340–2353.
   PubMed Web of Science ®Google Scholar
• Mao W, Deng F, Wang D, Gao L, Shi X. 2020. Treatment of advanced gallbladder cancer: a SEER-based study. Cancer Med. 9(1):141–150.
   PubMed Web of Science ®Google Scholar
• Pritchard CA, Hayes L, Wojnowski L, Zimmer A, Marais RM, Norman JC. 2004. B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts. Mol Cell Biol. 24(13):5937–5952.
   PubMed Web of Science ®Google Scholar
• Qian L, Su H, Wang G, Li B, Shen G, Gao Q. 2020. Anti-tumor activity of bufalin by inhibiting c-MET mediated MEK/ERK and PI3K/AKT signaling pathways in gallbladder cancer. J Cancer. 11(11):3114–3123.
   PubMed Web of Science ®Google Scholar
• Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P. 2009. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 69(21):8317–8325.
   PubMed Web of Science ®Google Scholar
• Roessler S, Edeline J, Schirmacher P, Coulouarn C. 2021. Integrative genomics highlights opportunities for innovative therapies targeting the tumor microenvironment in gallbladder cancer. J Hepatol. 74(5):1018–1020.
   PubMed Web of Science ®Google Scholar
• Satelli A, Li S. 2011. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 68(18):3033–3046.
   PubMed Web of Science ®Google Scholar
• Seo JY, Lim SS, Kim J, Lee KW, Kim JS. 2017. Alantolactone and isoalantolactone prevent amyloid β25-35-induced toxicity in mouse cortical neurons and scopolamine-induced cognitive impairment in mice. Phytother Res. 31(5):801–811.
   PubMed Web of Science ®Google Scholar
• Shen H, He M, Lin R, Zhan M, Xu S, Huang X, Xu C, Chen W, Yao Y, Mohan M, et al. 2019. PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway. J Exp Clin Cancer Res. 38(1):247.
   PubMed Web of Science ®Google Scholar
• Sobczak I, Galabova-Kovacs G, Sadzak I, Kren A, Christofori G, Baccarini M. 2008. B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis. Oncogene. 27(35):4779–4787.
   PubMed Web of Science ®Google Scholar
• Song X, Hu Y, Li Y, Shao R, Liu F, Liu Y. 2020. Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther. 5:230.
   PubMed Web of Science ®Google Scholar
• Tan X, Tamori Y, Egami H, Ishikawa S, Kurizaki T, Takai E, Hirota M, Ogawa M. 2004. Analysis of invasion-metastasis mechanism in pancreatic cancer: involvement of tight junction transmembrane protein occludin and MEK/ERK signal transduction pathway in cancer cell dissociation. Oncol Rep. 11:993–998.
   PubMed Web of Science ®Google Scholar
• Wang J, Cui L, Feng L, Zhang Z, Song J, Liu D, Jia X. 2016. Isoalantolactone inhibits the migration and invasion of human breast cancer MDA-MB-231 cells via suppression of the p38 MAPK/NF-κB signaling pathway. Oncol Rep. 36(3):1269–1276.
   PubMed Web of Science ®Google Scholar
• Weng Z, Gao H, Hu J, Fan Y, Wang H, Li L. 2016. Isoalantolactone induces autophagic cell death in SKOV3 human ovarian carcinoma cells via upregulation of PEA-15. Oncol Rep. 35(2):833–840.
   PubMed Web of Science ®Google Scholar
• Yang P, Javle M, Pang F, Zhao W, Abdel-Wahab R, Chen X, Meric-Bernstam F, Chen H, Borad MJ, Liu Y, et al. 2019. Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surg Nutr. 8(6):604–614.
   PubMed Web of Science ®Google Scholar